A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Next Previous
Trial Profile

A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jan 2018

At a glance

  • Drugs Apixaban (Primary) ; Enoxaparin sodium
  • Indications Venous thromboembolism
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 14 Sep 2017 Planned End Date changed from 27 Feb 2018 to 31 Dec 2018.
    • 14 Sep 2017 Planned primary completion date changed from 26 Feb 2018 to 30 Dec 2018.
    • 07 Oct 2016 Planned End Date changed from 1 Nov 2016 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top